 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA  Get Rating) has been given an average
  rating of Hold by the fourteen research firms that are covering the stock, MarketBeat
  Ratings reports. Ten analysts have rated the stock with a hold recommendation and
  three have assigned a buy ...


Analysts Set Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) PT at $99.20

---
- BNP Paribas Arbitrage SA lifted its holdings in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA  Get
  Rating) by 151.8% in the third quarter, according to the company in its most recent
  disclosure with the SEC. The institutional investor owned 15,076 shares of the biopharmaceutical
  companys ...


BNP Paribas Arbitrage SA Boosts Stock Position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

---
- 'At a stroke, the pharmaceutical company has become nearly $7 billion larger with
  a new asset.Hardly for the first time in the recent past, on Friday Pfizer (NYSE:
  PFE) stock landed in positive territory while the S&P 500 index sagged. The high-profile
  pharmaceutical company''s shares recorded a more-...'


Why Pfizer Stock Jumped While the Market Stumbled Today

---
- Shares of Pfizer Inc. were up 2.0% in trading on Friday after the company said it
  closed its $6.7 billion acquisition of Arena Pharmaceuticals Inc. Arena is developing
  treatments for immuno-inflammatory diseases like ulcerative colitis and atopic dermatitis.


Pfizer closes $6.7 billion acquisition of Arena Pharmaceuticals

---
- Invesco Ltd. cut its holdings in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA
  Get Rating) by 16.1% during the 3rd quarter, according to the company in its most
  recent Form 13F filing with the Securities & Exchange Commission. The fund owned
  45,255 shares of the biopharmaceutical companys stock...


Invesco Ltd. Reduces Position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

---
- 'This post contains sponsored advertising content. This content is for informational
  purposes only and not intended to be investing advice. Arena Pharmaceuticals Inc.
  (NASDAQ: ARNA) traded today at a new 12-month high of $100.00. Approximately 748,000
  shares have changed hands today, as compared to an average 30-day volume of 1.4
  million shares.'


Arena Pharmaceuticals Inc. Climbs To Annual-High Share Price

---
- Pfizer (PFE) confirmed that the HSR waiting period for its planned purchase of Arena
  Pharmaceuticals (ARNA) expired on Wednesday.The $6.7B acquisition of Arena (ARNA)
  is now expected...


Pfizer confirms HSR waiting period for Arena Pharmaceuticals deal expired

---
- Investors need to pay close attention to Arena (ARNA) stock based on the movements
  in the options market lately.
- ''
- " Investors in Arena Pharmaceuticals, Inc. ARNA need to pay close attention to the
  stock based on moves in the options market lately. That is because the Jul 15, 2022
  $90.00 Put had some ..."


Are Options Traders Betting on a Big Move in Arena (ARNA) Stock?

---
- This price move could be a signal that ARNA may fall back below the higher band
  and head toward the middle band. Traders may consider selling the stock, shorting
  the stock, or exploring put options...


Arena Pharmaceuticals (ARNA, $98.64) price may drop as it broke higher Bollinger Band on Mar 08, 2022

Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. Their leading drug candidate is lorcaserin hydrochloride, which recently received positive data from a clinical trial. They are headquartered in San Diego, CA.

Watchers	8,247
52-Wk Low	$45.50
52-Wk High	$100.00

Market Cap	$6.17B
Volume (M)	5.72M
52-Wk High	$100.00
52-Wk Low	$45.50

ARNA Arena Pharmaceuticals Inc

About

Feed

News

Fundamentals